‘Drugs to Watch’ list tags 11 about-to-be-approved therapies with blockbuster potential
Clarivate Analytics predicts both approvals and commercial potential
Clarivate Analytics, the London and Philadelphia-based market-research and consulting firm, has launched a “Drugs to Watch” listing that offers to predict both what drugs currently in in Phase II or III will be approved this year, and also their potential $1-billion blockbuster status in 2024.
The list (see figure) is dominated by biologics and includes one genetic therapy, Biomarin Pharmaceutical’s Valrox (valoctocogene roxaparvovec), that is expected to come to market with a price tag north of $2.5 million. The “one and done” therapy is a potential cure for hemophilia A.
Clarivate’s in-house Cortellis team uses a combination of financial and medical data to perform its analysis. Sources of intelligence include annual filings, drug pipelines, clinical trials, patents, chemistry, deals, conferences and company announcements. A second step in the review is clinical trial results, regulatory status, the market for each drug (including analysis of competitor drugs) and regulatory designations.
The Digital Transformation Reshaping Hospitals and Medication Management
January 20th 2025Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.
